Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

BACKGROUND: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesney, Jason, Lewis, Karl D, Kluger, Harriet, Hamid, Omid, Whitman, Eric, Thomas, Sajeve, Wermke, Martin, Cusnir, Mike, Domingo-Musibay, Evidio, Phan, Giao Q, Kirkwood, John M, Hassel, Jessica C, Orloff, Marlana, Larkin, James, Weber, Jeffrey, Furness, Andrew J S, Khushalani, Nikhil I, Medina, Theresa, Egger, Michael E, Graf Finckenstein, Friedrich, Jagasia, Madan, Hari, Parameswaran, Sulur, Giri, Shi, Wen, Wu, Xiao, Sarnaik, Amod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748991/
https://www.ncbi.nlm.nih.gov/pubmed/36600653
http://dx.doi.org/10.1136/jitc-2022-005755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748991/
https://www.ncbi.nlm.nih.gov/pubmed/36600653
http://dx.doi.org/10.1136/jitc-2022-005755

Ejemplares similares